

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)



(10) International Publication Number
WO 2020/127618 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/40 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2019/086143

(22) International Filing Date:

19 December 2019 (19.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18215121.7 21 December 2018 (21.12.2018) EP
19187709.1 23 July 2019 (23.07.2019) EP
19196006.1 06 September 2019 (06.09.2019) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **GEORGES, Guy**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **HOFFER, Thomas**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **HOSSE, Ralf**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **MOESSNER, Ekkehard**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **SAM, Johannes**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **UMAÑA, Pablo**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **THOM, Jenny Tosca**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **GASSER, Stephan**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **VALLIER, Jean-Baptiste Pierre**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FAUTI, Tanja**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **KLOSTERMEYER-RAUBER, Doerte**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES

(57) Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

WO 2020/127618 A1